Low Dose Anticancer Nano Drug (Nano Carbon)//Lung Cancer Application
Gyeongsang National University, California, United States
Suggested drug described at least ten-times reduction of anticancer drug amount using nanoparticles and thus demonstrated the evidence of diminishing the side effect comes by chemotherapy. This drug can be specific to lung and possibly effective to other malignant tumors. We are heading to enter clinical stages in near future.
Primary Application Area: Pharmaceuticals & Personal Care
Technology Development Status: Ready to Market
Technology Readiness Level: TRL 5
FIGURES OF MERIT
Value Proposition: This drug can reduce the amount of conventional anticancer drugs about 90-95%. Naturally, minimal dose of anti-cancer drugs will lessen the various side effects of drug during chemotherapy.
Organization Type: Academic/Gov Lab
Showcase Booth #: 904
GOVT/EXTERNAL FUNDING SOURCES
Government Funding/Support to Date: None (Not for developing stage but partially supported during toxicity test)
Primary Sources of Funding: Other
Looking for: Both Funding and Development Partners